StemCell Therapy

Myriad Genetics (NASDAQ: MYGN) and HTG Molecular Diagnostics (NASDAQ:HTGM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitabiliy, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Valuation and Earnings

This table compares Myriad Genetics and HTG Molecular Diagnostics revenue, earnings per share (EPS) and valuation.

Myriad Genetics has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Myriad Genetics and HTG Molecular Diagnostics net margins, return on equity and return on assets.

Institutional & Insider Ownership

28.0% of HTG Molecular Diagnostics shares are held by institutional investors. 6.2% of Myriad Genetics shares are held by insiders. Comparatively, 7.6% of HTG Molecular Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Myriad Genetics and HTG Molecular Diagnostics, as provided by MarketBeat.

Myriad Genetics presently has a consensus target price of $21.55, suggesting a potential downside of 13.44%. HTG Molecular Diagnostics has a consensus target price of $6.17, suggesting a potential upside of 175.30%. Given HTG Molecular Diagnostics stronger consensus rating and higher probable upside, analysts clearly believe HTG Molecular Diagnostics is more favorable than Myriad Genetics.

Volatility and Risk

Myriad Genetics has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500. Comparatively, HTG Molecular Diagnostics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500.

Summary

HTG Molecular Diagnostics beats Myriad Genetics on 7 of the 13 factors compared between the two stocks.

Myriad Genetics Company Profile

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individuals risk for developing disease later in life, identify a patients likelihood of responding to drug therapy and guide a patients dosing to enable optimal treatment, or assess a patients risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc. is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Companys HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development. The Companys HTG Edge and HTG EdgeSeq platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on a range of biological samples. The Companys HTG EdgeSeq chemistry, together with its HTG Edge or HTG EdgeSeq instrumentation and software, automates and adapts its nuclease protection chemistry to enable analysis using next generation sequencing (NGS) instrumentation. The HTG EdgeSeq system utilizes substantially the same sample preparation reagents as its original chemistry, but allows for read out on an NGS instrument.

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Excerpt from:
Analyzing Myriad Genetics (NASDAQ:MYGN) and HTG Molecular Diagnostics (HTGM) - BNB Daily (blog)

This entry was posted on August 7, 2017 at 12:43 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |